€35.30
0.98% yesterday
Xetra, Jun 13, 05:35 pm CET
ISIN
DE000A2GS5D8
Symbol
DMP
Index
Sector
Industry

Dermapharm Stock price

€35.30
-4.30 10.86% 1M
-2.40 6.37% 6M
-3.60 9.25% YTD
-1.20 3.29% 1Y
-8.45 19.31% 5Y
+9.30 35.77% 10Y
+9.30 35.77% 20Y
Xetra, Closing price Fri, Jun 13 2025
-0.35 0.98%
ISIN
DE000A2GS5D8
Symbol
DMP
Index
Sector
Industry

Key metrics

Market capitalization €1.92b
Enterprise Value €2.80b
P/E (TTM) P/E ratio 18.39
EV/FCF (TTM) EV/FCF 21.30
EV/Sales (TTM) EV/Sales 2.36
P/S ratio (TTM) P/S ratio 1.62
P/B ratio (TTM) P/B ratio 2.98
Dividend yield 2.55%
Last dividend (FY24) €0.90
Revenue growth (TTM) Revenue growth 6.24%
Revenue (TTM) Revenue €1.18b
EBIT (operating result TTM) EBIT €211.03m
Free Cash Flow (TTM) Free Cash Flow €131.29m
Cash position €118.02m
EPS (TTM) EPS €1.92
P/E forward 15.18
P/S forward 1.61
EV/Sales forward 2.34
Show more

Is Dermapharm a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Dermapharm Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Dermapharm forecast:

5x Buy
83%
1x Hold
17%

Analyst Opinions

6 Analysts have issued a Dermapharm forecast:

Buy
83%
Hold
17%

Financial data from Dermapharm

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
1,184 1,184
6% 6%
100%
- Direct Costs 417 417
2% 2%
35%
767 767
9% 9%
65%
- Selling and Administrative Expenses 286 286
7% 7%
24%
- Research and Development Expense - -
-
-
302 302
10% 10%
25%
- Depreciation and Amortization 91 91
17% 17%
8%
EBIT (Operating Income) EBIT 211 211
28% 28%
18%
Net Profit 104 104
83% 83%
9%

In millions EUR.

Don't miss a Thing! We will send you all news about Dermapharm directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Dermapharm Stock News

AD HOC NEWS
about one month ago
Der Arzneimittelhersteller Dermapharm DE000A2GS5D8 ist zum Jahresstart dank guter Geschäfte mit Markenarzneien leicht gewachsen.
AD HOC NEWS
about one month ago
Der Arzneimittelhersteller Dermapharm DE000A2GS5D8 ist zum Jahresstart dank guter Geschäfte mit Markenarzneien leicht gewachsen.
AD HOC NEWS
2 months ago
Die Privatbank Berenberg hat das Kursziel für Dermapharm DE000A2GS5D8 nach endgültigen Jahreszahlen von 50 auf 44 Euro gesenkt, die Einstufung auf "Buy" belassen.
More Dermapharm News

Company Profile

Dermapharm Holding SE engages in the development, manufacture. and market of patent-free pharmaceutical products. The company also involves in in-house development, in-house production, and distribution of pharmaceuticals and other healthcare products. It offers its products through the following brands: Dekristol 20,000 I.E., bite away, Herpotherm, sikapur, Ampho-Moronal, Solacutan, Ciclocutan, Minoxicutan, Prednisolut, Dienovel, Lactofem, Finapil, Panthenol-Augensalbe JENAPHARM, and Suxilep. The company was founded in 1991 and is headquartered in Grunwald, Germany.

Head office Germany
CEO Hans-Georg Feldmeier
Employees 3,610
Founded 1991
Website ir.dermapharm.de

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today